EGFR and ovarian cancer: A recent phase II trial in women with predominantly platinum-resistant recurrent ovarian cancer concluded that vandetanib, a multikinase inhibitor designed to perturb both angiogenesis (i.e., VEGFR) and tumor cell growth (i.e., EGFR), did not produce translational clinical benefit since the drug inhibited EGFR and AKT levels in tumor biopsies, but had no effect on VEGFR [164].